CLARITIN HIVES RELIEF REDITAB Drug Patent Profile

When do Claritin Hives Relief Reditab patents expire, and when can generic versions of Claritin Hives Relief Reditab launch?

Claritin Hives Relief Reditab is a drug marketed by Bayer Healthcare Llc and is included in one NDA.

The generic ingredient in CLARITIN HIVES RELIEF REDITAB is loratadine. There are thirty-nine drug master file entries for this compound. One hundred and fifty-seven suppliers are listed for this compound. Additional details are available on the loratadine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Claritin Hives Relief Reditab

A generic version of CLARITIN HIVES RELIEF REDITAB was approved as loratadine by PLD ACQUISITIONS LLC on January 21^st, 2003.

Summary for CLARITIN HIVES RELIEF REDITAB

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	148
DailyMed Link:	CLARITIN HIVES RELIEF REDITAB at DailyMed

US Patents and Regulatory Information for CLARITIN HIVES RELIEF REDITAB

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Healthcare Llc	CLARITIN HIVES RELIEF REDITAB	loratadine	TABLET, ORALLY DISINTEGRATING;ORAL	020704-003	Nov 19, 2003		OTC	Yes	Yes

International Patents for CLARITIN HIVES RELIEF REDITAB

See the table below for patents covering CLARITIN HIVES RELIEF REDITAB around the world.

Country	Patent Number	Title	Estimated Expiration
Israel	63122	ANTIHISTAMINIC TRICYCLIC ALKYLCARBAMIC AND SULFAMIC ACID ESTERS,THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
Hungary	194864	PROCESS FOR PRODUCTION OF 8-CHLOR-6,11-DIHYDRO-11-(4-PIPERIDILIDENE)-5H-BENZO (5,6)-CYCLO-HEPTA (1,2-B) PYRIDINE AND ITS SALTS
Kenya	3171	PHARMACEUTICAL DOSAGE FORMS
Hungary	T41731
United Kingdom	1548022

Supplementary Protection Certificates for CLARITIN HIVES RELIEF REDITAB

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1110543	08C0004	France		PRODUCT NAME: DESLORATADINE; PSEUDOEPHEDRINE SULFATE; REGISTRATION NO/DATE: EU/1/07/399/001 20070730
0152897	SPC/GB01/012	United Kingdom		PRODUCT NAME: DESLORATADINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/00/157/001-013 20010115; UK EU/1/00/158/001-013 20010115; UK EU/1/00/159/001-013 20010115; UK EU/1/00/160/001-013 20010115; UK EU/1/00/161/001-013 20010115
0152897	2001C/013	Belgium		PRODUCT NAME: DESLORATADINE; REGISTRTION NO/DATE: EU/1/00/160/010 20010115
1110543	SPC/GB08/005	United Kingdom		SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/005 GRANTED TO MERCK SHARP + DOHME CORP. IN RESPECT OF THE PRODUCT DESLORATADINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN COMBINATION WITH PSEUDOEPHEDRINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6322 DATED 21 JULY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 JULY 2022.
0152897	C00152897/01	Switzerland		FORMER REPRESENTANTIVE: E. BLUM AND CO. PATENTANWAELTE, CH

Market Dynamics and Financial Trajectory for CLARITIN Hives Relief Reditab

Last updated: February 19, 2026

What is the current market positioning of CLARITIN Hives Relief Reditab?

CLARITIN Hives Relief Reditab is a non-prescription allergy medication primarily indicated for symptomatic relief of hives and allergic skin reactions. Its active ingredient, loratadine, is a second-generation antihistamine with a well-established profile for safety and efficacy. The medication competes in the adult OTC antihistamine market, with a focus on allergic dermatological conditions.

Market share in the US OTC antihistamine segment positions Claritin as a leading brand, with annual sales exceeding $1.5 billion in recent years (IQVIA, 2022). The product faces competition from generics and other OTC brands such as Zyrtec, Allegra, and generic loratadine formulations.

How does the regulatory environment influence its market dynamics?

The drug's regulatory journey includes:

• FDA Approval: Claritin was approved in 1993, with the OTC switch occurring in 2002.

• Patent Status: The primary patent expired in 2002; however, formulation patents extended exclusivity in certain markets, delaying generic entry until 2015-2016.

• Regulatory barriers: Strict labeling and OTC classification standards enforce consistent marketing, but ease competition from generics.

Regulatory exclusivity periods contribute to sustained revenue; once expired, generic competition significantly reduces prices and market share.

What are the key drivers of market growth?

The expanding prevalence of allergies, especially conjunctivitis and urticaria, supports demand growth. The global allergy market is expected to reach $30 billion by 2027, with OTC antihistamines constituting a major segment (Market Research Future, 2021).

Consumer demand for trusted OTC options, driven by awareness of side effects associated with first-generation antihistamines, sustains growth of drugs like Claritin. The aging population further increases demand, as allergic conditions are more common among older adults.

What are the competitive challenges impacting financial performance?

• Price erosion: Entry of generics post-patent expiry causes significant revenue decline. The 2016 launch of generic loratadine reduced brand sales by 60% within a year.

• Market saturation: Numerous similar OTC antihistamines saturate the market, limiting growth potential.

• Pricing pressure: Retailers and pharmacies favor lower-cost generics, with brand-name sales compromised.

• Regulatory shifts: Future labeling or safety regulations could impact formulations and marketing strategies.

How do sales trends project into future revenue?

Pre-patent expiration, Claritin’s global sales hovered around $2 billion annually. Post-patent expiry, sales plummeted in the US, with a steep decline to approximately $600 million by 2018 (IQVIA, 2022). Recently, sales have stabilized around $800 million annually, driven by international markets and new formulations.

The future trajectory depends largely on:

• Expansion into emerging markets with rising allergy prevalence.
• Development of reformulations with improved formulations or delivery methods.
• Strategic diversification within allergy-related indications or combination products.

What financial strategies could influence Claritin’s market position?

• Diversification: Introducing new formulations (e.g., fast-acting tablets, suspensions) or combination products targeting multiple allergic symptoms.

• Pricing strategies: Managing generic competition through downward price adjustments or value-added packaging.

• Market expansion: Focusing on developing countries with expanding healthcare access and increasing allergic disease awareness.

• Regulatory lobbying: Securing future patent protections or exclusivity through formulation patents or delivery route innovations.

What is the outlook for key competitors?

• Zyrtec (cetirizine): Maintains strong market share, with annual sales around $750 million in the US.

• Allegra (fexofenadine): Generates close to $600 million annually in the US.

• Generics: Market share continues to increase with low-cost options, putting pressure on brand-name drugs.

International markets represent growth opportunities, yet regulatory hurdles and market access costs impact expansion velocity.

Summary of financial significance

Year	US Sales (millions USD)	Key Drivers
2015	1,200	Patent protection, brand loyalty
2016	600	Patent expiry, rise of generics
2018	600	Market stabilization, generic competition
2022	800	International growth, new formulations

Key Takeaways

• Claritin’s market dominance diminished following patent expiration but remains a substantial player in international markets.
• Generics dominate US sales, significantly reducing brand revenue.
• The global allergy market’s growth offers opportunities, especially in developing countries.
• Future revenue depends on innovation, market expansion, and price management.
• Competitive landscape is highly saturated with close substitutes, emphasizing importance of differentiation.

FAQs

1. Will Claritin regain market share post-patent expiry?
Market share recovery is unlikely without new formulations or indications; generic competition caps potential gains.

2. What strategies could prolong Claritin’s profitability?
Innovation through new delivery methods, expanding into emerging markets, and patenting combination formulations.

3. How do generics impact Claritin’s future revenues?
Generics have significantly eroded US revenues since 2016; international markets remain largely unaffected, offering growth avenues.

4. Are there regulatory hurdles for expanding Claritin’s indications?
Yes, approval of new indications depends on clinical trial data and FDA regulatory pathways that can prolong time-to-market.

5. What is the potential for Claritin in pediatric allergy markets?
Pediatric formulations and indications are growing segments, but regulatory approval processes are rigorous, and competition is intense.

---

References

1. IQVIA (2022). Pharmaceutical Market Data. IQVIA Institute for Human Data Science.
2. Market Research Future (2021). Global Allergy Market Report. MRFR.
3. U.S. Food and Drug Administration (FDA). (2002). OTC Drug Monograph Final.
4. U.S. Patent and Trademark Office (USPTO). (2022). Patent status for loratadine.
5. Statista (2022). Antihistamine Market Revenue by Region.